How many employees does PTC Therapeutics, Inc. have?

PTC Therapeutics, Inc. reported 991 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 19, 2026. That is up 5.5% from a year earlier.

What is PTC Therapeutics, Inc.'s revenue per employee?

PTC Therapeutics, Inc. brought in $1.73B of revenue in fiscal Dec 2025, which is $1.75M per employee. That ranks 7 of 39 companies we track in Biotechnology, where the median is $602K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

PTC Therapeutics, Inc. employees and revenue per employee

PTCT · Biotechnology · $5.77B market cap

PTC Therapeutics, Inc. had 991 employees at the end of fiscal Dec 2025, up 5.5% from a year earlier. Revenue for the year was $1.73B, up 114.5% from a year earlier, or $1.75M per employee. Revenue and headcount both grew, and revenue grew faster.

Employees

991

+5.5% YoY

Revenue

$1.73B

+114.5% YoY

Revenue / employee

$1.75M

Peer median $602K

Rank in industry

7 of 39

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016

Hover a year for the numbers.

PTCT employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	991	$1.73B	$1.75M	+5.5%	+114.5%
Dec 2024	939	$807M	$859K	-5.0%	-14.0%
Dec 2023	988	$938M	$949K	-29.5%	+34.2%
Dec 2022	1,402	$699M	$498K	+20.1%	+29.7%
Dec 2021	1,167	$539M	$462K	+21.7%	+41.4%
Dec 2020	959	$381M	$397K	+27.2%	+24.0%
Dec 2019	754	$307M	$407K	+45.8%	+16.0%
Dec 2018	517	$265M	$512K	+41.3%	+36.2%
Dec 2017	366	$194M	$531K	+20.4%	+135.0%
Dec 2016	304	$82.7M	$272K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

PTC Therapeutics, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
HALO Halozyme Therapeutics, Inc.	423	$1.40B	$3.30M	Efficient growth
EXEL Exelixis, Inc.	1,077	$2.32B	$2.15M	Leaner
PTCT PTC Therapeutics, Inc.	991	$1.73B	$1.75M	Efficient growth
NBIX Neurocrine Biosciences, Inc.	2,000	$2.86B	$1.43M	Efficient growth
MDGL Madrigal Pharmaceuticals, Inc.	915	$958M	$1.05M	Efficient growth
MRNA Moderna, Inc.	4,700	$1.94B	$414K	Contracting
TECH Bio-Techne Corporation	3,000	$1.22B	$405K	Contracting
LEGN Legend Biotech Corporation	2,900	$1.03B	$355K	Efficient growth
FTRE Fortrea Holdings Inc.	14,300	$2.72B	$190K	Leaner

Every Healthcare company

Questions about PTC Therapeutics, Inc.

How many employees does PTC Therapeutics, Inc. have?: PTC Therapeutics, Inc. reported 991 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 19, 2026. That is up 5.5% from a year earlier.
What is PTC Therapeutics, Inc.'s revenue per employee?: PTC Therapeutics, Inc. brought in $1.73B of revenue in fiscal Dec 2025, which is $1.75M per employee. That ranks 7 of 39 companies we track in Biotechnology, where the median is $602K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare PTCT with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in PTC Therapeutics, Inc.'s annual reports (Form 10-K), latest filed February 19, 2026. This is data, not a recommendation to buy or sell PTCT.